Anticytokine Therapies in Systemic Lupus Erythematosus

• Mok CC : Update on emerging drug therapies for systemic lupus erythematosus.Expert Opin. Emerg. Drugs15(1) , 53–70 (2010).
   PubMed Web of Science ®Google Scholar
• Jacob C , McDevittH: Tumour necrosis factor-α in murine autoimmune ‘lupus‘ nephritis.Nature331(6154) , 356–358 (1988).
   PubMed Web of Science ®Google Scholar
• Brennan D , YuiM, WuthrichR, KelleyV: Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury.J. Immunol.143(11) , 3470–3475 (1989).
   PubMed Web of Science ®Google Scholar
• Edwards C , ZhouT, ZhangJet al.: Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α.J. Immunol.157(4) , 1758–1772 (1996).
   PubMed Web of Science ®Google Scholar
• Yokoyama H , KreftB, KelleyV: Biphasic increase in circulating and renal TNF-α in MRL-lpr mice with differing regulatory mechanisms.Kidney Int.47(1) , 122–130 (1995).
   PubMed Web of Science ®Google Scholar
• Aringer M , SmolenJ: SLE – complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus.Arthritis Res. Ther.5(4) , 172–177 (2003).
   PubMed Web of Science ®Google Scholar
• Gabay C , CakirN, MoralFet al.: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.J. Rheumatol.24(2) , 303–308 (1997).
   PubMed Web of Science ®Google Scholar
• Lacki J , LeszczynskiP, KelemenJ, MüllerW, MackiewiczS: Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response.J. Med.28(1–2) , 99–107 (1997).
   PubMedGoogle Scholar
• Studnicka-Benke A , SteinerG, PeteraP, SmolenJ: Tumour necrosis factor a and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus.Br. J. Rheumatol.35(11) , 1067–1074 (1996).
   PubMedGoogle Scholar
• Charles P , SmeenkR, De Jong J, Feldmann M, Maini R: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum.43(11) , 2383–2890 (2000).
   PubMed Web of Science ®Google Scholar
• De Rycke L , KruithofE, Van Damme N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum.48(4) , 1015–1023 (2003).
   PubMed Web of Science ®Google Scholar
• Shakoor N , MichalskaM, HarrisC, BlockJ: Drug-induced systemic lupus erythematosus associated with etanercept therapy.Lancet359(9306) , 579–580 (2002).
   PubMed Web of Science ®Google Scholar
• Carlson E , RothfieldN: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.Arthritis Rheum.48(4) , 1165–1166 (2003).
   PubMedGoogle Scholar
• Stokes M , FosterK, MarkowitzGet al.: Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis.Nephrol. Dial. Transplant.20(7) , 1400–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Aringer M , SteinerG, GraningerWet al.: Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.Arthritis Rheum.56(1) , 274–279 (2007).
   PubMedGoogle Scholar
• Hayat S , UppalS: Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus.Mod. Rheumatol.17(2) , 174–177 (2007).
   PubMedGoogle Scholar
• Aringer M , GraningerWB, SteinerG, SmolenJ: Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open label study.Arthritis Rheum.50(10) , 3161–3169 (2004).
   PubMed Web of Science ®Google Scholar
• Feng X , WuH, GrossmanJet al.: Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.Arthritis Rheum.54(9) , 2951–2962 (2006).
   PubMedGoogle Scholar
• Baechler E , BatliwallaF, KarypisGet al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.Proc. Natl Acad. Sci. USA100(5) , 2610–2615 (2003).
   PubMed Web of Science ®Google Scholar
• Bengtsson A , SturfeltG, TruedssonLet al.: Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies.Lupus9(9) , 664–671 (2000).
   PubMed Web of Science ®Google Scholar
• Balomenos D , RumoldR, TheofilopoulosA: Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.J. Clin. Invest.101(2) , 364–371 (1998).
   PubMed Web of Science ®Google Scholar
• Jacob C , van der Meide P, McDevitt H: In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to g interferon. J. Exp. Med.166(3) , 798–803 (1987).
   PubMed Web of Science ®Google Scholar
• Lawson B , Prud‘hommeG, ChangYet al.: Treatment of murine lupus with cDNA encoding IFN-γR/Fc.J. Clin. Invest.106(2) , 207–215 (2000).
   PubMed Web of Science ®Google Scholar
• Nicoletti F , Di Marco R, Zaccone P et al.: Dichotomic effects of IFN-γ on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur. J. Immunol.30(2) , 438–447 (2000).
   PubMed Web of Science ®Google Scholar
• Uhm W , NaK, SongGet al.: Cytokine balance in kidney tissue from lupus nephritis patients.Rheumatology (Oxford)42(8) , 935–938 (2003).
   PubMed Web of Science ®Google Scholar
• Min D , ChoM, ChoCet al.: Decreased production of interleukin-12 and interferon-γ is associated with renal involvement in systemic lupus erythematosus.Scand. J. Rheumatol.30(3) , 159–163 (2001).
   PubMed Web of Science ®Google Scholar
• Horai R , SaijoS, TaniokaHet al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice.J. Exp. Med.191(2) , 313–320 (2000).
   PubMed Web of Science ®Google Scholar
• Kiberd B , StadnykA: Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule?Immunopharmacology30(2) , 131–137 (1995).
   PubMedGoogle Scholar
• Takemura T , YoshiokaK, MurakamiKet al.: Cellular localization of inflammatory cytokines in human glomerulonephritis.Virchows Arch. 424 (5) , 459–464 (1994).
   Google Scholar
• Sturfelt G , Roux-LombardP, WollheimF, DayerJ: Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.Br. J. Rheumatol.36(12) , 1283–1289 (1997).
   PubMedGoogle Scholar
• Suzuki H , TakemuraH, KashiwagiH: Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity.Arthritis Rheum.38(8) , 1055–1059 (1995).
   PubMedGoogle Scholar
• Ostendorf B , Iking-KonertC, KurzKet al.: Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.Ann. Rheum. Dis.64(4) , 630–633 (2005).
   PubMed Web of Science ®Google Scholar
• Kiberd B : Interleukin-6 receptor blockage ameliorates murine lupus nephritis.J. Am. Soc. Nephrol.4(1) , 58–61 (1993).
   PubMed Web of Science ®Google Scholar
• Finck BK , ChanB, WofsyD: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.J. Clin. Invest.94(2) , 585–591 (1994).
   PubMed Web of Science ®Google Scholar
• Stuart R , LittlewoodA, MaddisonP, HallN: Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders.Clin. Exp. Rheumatol.13(1) , 17–22 (1995).
   PubMed Web of Science ®Google Scholar
• Horii Y , IwanoM, HirataEet al.: Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis.Kidney Int.39 , S71–75 (1993).
   Google Scholar
• Yoshio T , MasuyamaJ, KohdaNet al.: Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE.J. Rheumatol.24(3) , 489–495 (1997).
   PubMed Web of Science ®Google Scholar
• Alcocer-Varela J , Aleman-HoeyD, Alarcon-SegoviaD: Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers.Lupus1(2) , 111–117 (1992).
   PubMed Web of Science ®Google Scholar
• Illei GG , ShirotaY, YarboroCHet al.: Tocilizumab in systemic lupus erythematosus. data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label Phase I dosage-escaltion study.Arthritis Rheum.62(2) , 542–552 (2010).
   PubMed Web of Science ®Google Scholar
• Ishida H , MuchamuelT, SakaguchiSet al.: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice.J. Exp. Med.179(1) , 305–310 (1994).
   PubMed Web of Science ®Google Scholar
• Yin Z , BahtiyarG, ZhangNet al.: IL-10 regulates murine lupus.J. Immunol.169(4) , 2148–2155 (2002).
   PubMed Web of Science ®Google Scholar
• Houssiau F , LefebvreC, Vanden Berghe M et al.: Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus4(5) , 393–395 (1995).
   PubMed Web of Science ®Google Scholar
• Llorente L , ZouW, LevyYet al.: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.J. Exp. Med.181(3) , 839–844 (1995).
   PubMed Web of Science ®Google Scholar
• Llorente L , Richaud-PatinY, CoudercJet al.: Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus.Arthritis Rheum.40(8) , 1429–1435 (1997).
   PubMed Web of Science ®Google Scholar
• Llorente L , Richaud-PatinY, García-PadillaCet al.: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.Arthritis Rheum.43(8) , 1790–1800 (2000).
   PubMed Web of Science ®Google Scholar
• Litinskiy M , NardelliB, HilbertDet al.: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.Nat. Immunol.3(9) , 822–829 (2002).
   PubMed Web of Science ®Google Scholar
• Scapini P , NardelliB, NadaliGet al.: G-CSF-stimulated neutrophils are a prominent source of functional BLyS.J. Exp. Med.197(3) , 297–302 (2003).
   PubMed Web of Science ®Google Scholar
• Gross J , DillonS, MudriSet al.: TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS.Immunity15(2) , 289–302 (2001).
   PubMed Web of Science ®Google Scholar
• Stohl W , MetyasS, TanSet al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.Arthritis Rheum.48(12) , 3475–3486 (2003).
   PubMed Web of Science ®Google Scholar
• Stohl W : SLE – systemic lupus erythematosus: a BLySful, yet BAFFling, disorder.Arthritis Res. Ther.5(3) , 136–138 (2003).
   PubMed Web of Science ®Google Scholar
• Ng L , SutherlandA, NewtonRet al.: B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells.J. Immunol.173(2) , 807–817 (2004).
   PubMed Web of Science ®Google Scholar
• Cancro MP , D‘CruzDP, KhamashtamMA: The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.J. Clin. Invest.119(5) , 1066–1073 (2009).
   PubMed Web of Science ®Google Scholar
• Seshasayee D , ValdezP, YanMet al.: Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.Immunity18(2) , 279–288 (2003).
   PubMed Web of Science ®Google Scholar
• Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs RD9(3) , 197–202 (2008).
   PubMed Web of Science ®Google Scholar
• von Bülow G , van Deursen J, Bram R: Regulation of the T-independent humoral response by TACI. Immunity14(5) , 573–582 (2001).
   PubMed Web of Science ®Google Scholar
• Lee C , HymowitzS, WallweberHet al.: Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells.Blood108(9) , 3103–3111 (2006).
   PubMed Web of Science ®Google Scholar
• Lin W , GongQ, SeshasayeeDet al.: Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.Blood110(12) , 3959–3967 (2007).
   PubMed Web of Science ®Google Scholar
• Stohl W , MerrillJT, LooneyRJet al.: Phase 1a single- and Phase 1b multiple-dose studies of AMG 623 (an anti-BAFF peptibody) in systemic lupus erythematosus (SLE).Arthritis Rheum.58(9) , S565–S566 (2008).
   Google Scholar
• Fleischmann R , WeiN, ShawMet al.: BR3-Fc Phase I study: safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects of a novel BR3-Fc fusion protein in patients with rheumatoid arthritis.Arthritis Rheum.54(9) , S229–S230 (2006).
   Web of Science ®Google Scholar
• Ratner M : Human Genome Sciences trial data wow lupus community.Nat. Biotechnol.27(9) , 779–780 (2009).
   PubMed Web of Science ®Google Scholar

▪ Website

• BENLYSTA® (belimumab) www.hgsi.com/belimumab.html
   Google Scholar